Caxton Corp
- SEC CIK
- 0001388551
- Latest filing
- Aug 13, 2026
Holdings in Q2 2025
Holdings as of Jun 30, 2025, filed Aug 14, 2025. Long positions only; changes compare share counts with Q1 2025.
- Positions
- 11
- −1 vs. Q1 2025
- Portfolio value
- $9.85M
- +$4.77M (+93.9%) vs. Q1 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| RZLTRezolute, Inc. | COM NEW | 1,603,986 | $7.15M | 72.6% | +285,019+21.6% | Added | History |
| GLDSPDR Gold Trust | ETF | 4,952 | $1.51M | 15.3% | +3,654+281.5% | Added | History |
| BRK.BBerkshire Hathaway Inc | Stock | 632 | $307.0K | 3.1% | +165+35.3% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 13,097 | $262.7K | 2.7% | +13,097 | New | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 34,073 | $221.1K | 2.2% | 00.0% | Unchanged | History |
| CMPXCompass Therapeutics, Inc. | COM | 43,465 | $113.0K | 1.1% | 00.0% | Unchanged | History |
| BCAXBicara Therapeutics Inc. | COM | 10,941 | $101.6K | 1.0% | 00.0% | Unchanged | History |
| KYTXKyverna Therapeutics, Inc. | COM | 22,981 | $70.6K | 0.7% | 00.0% | Unchanged | History |
| LXEOLexeo Therapeutics, Inc. | COM | 17,332 | $69.7K | 0.7% | −519−2.9% | Reduced | History |
| IKTInhibikase Therapeutics, Inc. | COM NEW | 16,393 | $32.0K | 0.3% | 00.0% | Unchanged | History |
| CNTXContext Therapeutics Inc. | COM | 18,403 | $12.1K | 0.1% | 00.0% | Unchanged | History |
Sold out since Q1 2025 (2)
Positions held at the end of Q1 2025 that are gone from this filing.